SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Apr 19, 2013
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: April 19, 2013 · CIK: 0001130166 · Accession: 0001104659-13-030971
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-187801
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Austin Stephenson, Esq. Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-3 Initially Filed on April 8, 2013, as amended on April 18, 2013 File No. 333-187801
Dear Mr. Stephenson:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Monday, April 22, 2013 at 4:00 p.m., or as soon as practicable thereafter.
In connection with the foregoing request, the Company acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Joel I. Papernik of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6774 with any comments or questions regarding the Registration Statement.
Very truly yours,
/s/ Paul McBarron
Show Raw Text
CORRESP 1 filename1.htm Cyclacel Pharmaceuticals, Inc. April 19, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Austin Stephenson, Esq. Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-3 Initially Filed on April 8, 2013, as amended on April 18, 2013 File No. 333-187801 Dear Mr. Stephenson: With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Monday, April 22, 2013 at 4:00 p.m., or as soon as practicable thereafter. In connection with the foregoing request, the Company acknowledges the following: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Joel I. Papernik of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6774 with any comments or questions regarding the Registration Statement. Very truly yours, /s/ Paul McBarron Paul McBarron Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer x 200 Connell Drive #1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 (866) 271 3466 o Dundee Technopole, 1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067 www.cyclacel.com – info@cyclacel.com